5th Apr 2011 14:34
Epistem Holdings Plc ("Epistem" or the "Company")
Directors' Shareholdings
Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.
As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors have each increased their beneficial interest in the Company by 198 ordinary shares of 1.5p each. These shares were acquired on 31 January 2011 and 1 March 2011 at prices of 388p and 380p respectively.
The current beneficial interests of the executive Directors are set out below:
Matthew Walls 7,984 (0.10%)
Dr Catherine Booth 982,339 (12.38%)
Dr Ged Brady 2,339 (0.03%)
Dr Jeffrey Moore 16,839 (0.21%)
John Rylands 192,237 (2.42%)
For further details please contact:
Epistem Plc
Matthew Walls, CEO +44 161 606 7258
John Rylands, Finance Director +44 161 606 7244
Peel Hunt LLP
James Steel / Vijay Barathan +44 20 7418 8900
Related Shares:
Genedrive